135 related articles for article (PubMed ID: 20945990)
1. Cytokine patterns after therapy with Avonex®, Rebif®, Betaferon® and CinnoVex™ in relapsing-remitting multiple sclerosis in Iranian patients.
Arababadi MK; Mosavi R; Khorramdelazad H; Yaghini N; Zarandi ER; Araste M; Pourali R; Nekhei Z; Kennedy D
Biomark Med; 2010 Oct; 4(5):755-9. PubMed ID: 20945990
[TBL] [Abstract][Full Text] [Related]
2. Serum levels of IL-17A in patients with relapsing-remitting multiple sclerosis treated with interferon-β.
Bălaşa R; Bajko Z; Huţanu A
Mult Scler; 2013 Jun; 19(7):885-90. PubMed ID: 23207971
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Betaferon, Avonex, and Rebif in treatment of relapsing-remitting multiple sclerosis.
Etemadifar M; Janghorbani M; Shaygannejad V
Acta Neurol Scand; 2006 May; 113(5):283-7. PubMed ID: 16629762
[TBL] [Abstract][Full Text] [Related]
4. Time-dependent cytokine deviation toward the Th2 side in Japanese multiple sclerosis patients with interferon beta-1b.
Ochi H; Feng-Jun M; Osoegawa M; Minohara M; Murai H; Taniwaki T; Kira J
J Neurol Sci; 2004 Jul; 222(1-2):65-73. PubMed ID: 15240198
[TBL] [Abstract][Full Text] [Related]
5. IFN-beta1a and IFN-beta1b have different patterns of influence on cytokines.
Sega S; Wraber B; Mesec A; Horvat A; Ihan A
Clin Neurol Neurosurg; 2004 Jun; 106(3):255-8. PubMed ID: 15177779
[TBL] [Abstract][Full Text] [Related]
6. Assessment of Interleukin-17A, Interleukin-10 and Transforming Growth Factor-Beta1 Serum Titers in Relapsing Remitting Multiple Sclerosis Patients Treated with Avonex, Possible Biomarkers for Treatment Response.
Balasa R; Maier S; Voidazan S; Hutanu A; Bajko Z; Motataianu A; Tilea B; Tiu C
CNS Neurol Disord Drug Targets; 2017; 16(1):93-101. PubMed ID: 27306062
[TBL] [Abstract][Full Text] [Related]
7. An Intricate Mechanism of Action of Avonex in Relapsing Remitting Multiple Sclerosis Patients: Variation of Serum Titre of Interleukin-17A, Interleukin-10 and Transforming Growth Factor-β.
Balasa R; Maier S; Voidazan S; Hutanu A; Bajko Z; Motataianu A
CNS Neurol Disord Drug Targets; 2015; 14(6):804-10. PubMed ID: 25801840
[TBL] [Abstract][Full Text] [Related]
8. Short-term treatment of relapsing remitting multiple sclerosis patients with interferon (IFN)-beta1B transiently increases the blood levels of interleukin (IL)-6, IL-10 and IFN-gamma without significantly modifying those of IL-1beta, IL-2, IL-4 and tumour necrosis factor-alpha.
Nicoletti F; Di Marco R; Patti F; Zaccone P; L'Episcopo MR; Reggio E; Xiang M; Nicoletti A; Reggio A
Cytokine; 2000 Jun; 12(6):682-7. PubMed ID: 10843745
[TBL] [Abstract][Full Text] [Related]
9. Comparing efficacy and side effects of a weekly intramuscular biogeneric/biosimilar interferon beta-1a with Avonex in relapsing remitting multiple sclerosis: a double blind randomized clinical trial.
Nafissi S; Azimi A; Amini-Harandi A; Salami S; shahkarami MA; Heshmat R
Clin Neurol Neurosurg; 2012 Sep; 114(7):986-9. PubMed ID: 22429566
[TBL] [Abstract][Full Text] [Related]
10. Quantitative differences in the immunomodulatory effects of Rebif and Avonex in IFN-β 1a treated multiple sclerosis patients.
Christophi GP; Christophi JA; Gruber RC; Mihai C; Mejico LJ; Massa PT; Jubelt B
J Neurol Sci; 2011 Aug; 307(1-2):41-5. PubMed ID: 21658727
[TBL] [Abstract][Full Text] [Related]
11. Increased IL-10 mRNA and IL-23 mRNA expression in multiple sclerosis: interferon-beta treatment increases IL-10 mRNA expression while reducing IL-23 mRNA expression.
Krakauer M; Sorensen P; Khademi M; Olsson T; Sellebjerg F
Mult Scler; 2008 Jun; 14(5):622-30. PubMed ID: 18424480
[TBL] [Abstract][Full Text] [Related]
12. Clinical and laboratory study of pro-inflammatory and antiinflammatory cytokines in women with multiple sclerosis.
Trenova AG; Manova MG; Kostadinova II; Murdjeva MA; Hristova DR; Vasileva TV; Zahariev ZI
Folia Med (Plovdiv); 2011; 53(2):29-35. PubMed ID: 21797104
[TBL] [Abstract][Full Text] [Related]
13. Interferon-beta (INF-beta) antibodies in interferon-beta1a- and interferon-beta1b-treated multiple sclerosis patients. Prevalence, kinetics, cross-reactivity, and factors enhancing interferon-beta immunogenicity in vivo.
Perini P; Facchinetti A; Bulian P; Massaro AR; Pascalis DD; Bertolotto A; Biasi G; Gallo P
Eur Cytokine Netw; 2001 Mar; 12(1):56-61. PubMed ID: 11282547
[TBL] [Abstract][Full Text] [Related]
14. Early identification of interferon-beta responders by ex vivo testing in patients with multiple sclerosis.
Wiesemann E; Deb M; Hemmer B; Radeke HH; Windhagen A
Clin Immunol; 2008 Sep; 128(3):306-13. PubMed ID: 18539537
[TBL] [Abstract][Full Text] [Related]
15. Frequency and severity of headache is worsened by Interferon-β therapy in patients with multiple sclerosis.
Patti F; Nicoletti A; Pappalardo A; Castiglione A; Lo Fermo S; Messina S; D'Amico E; Cimino V; Zappia M
Acta Neurol Scand; 2012 Feb; 125(2):91-5. PubMed ID: 21649611
[TBL] [Abstract][Full Text] [Related]
16. Determination of cytokine levels in multiple sclerosis patients and their relevance with patients' response to Cinnovex.
Taheri M; Ghafouri-Fard S; Solgi G; Sayad A; Mazdeh M; Omrani MD
Cytokine; 2017 Aug; 96():138-143. PubMed ID: 28399486
[TBL] [Abstract][Full Text] [Related]
17. [Experience in the treatment of multiple sclerosis with interferon beta in Galicia].
Romero-López J; Seijo-Martínez M; Del Campo V; Amigo-Jorrín MC; Arias M; Cortés-Laíño JA; Dapena-Bolaño D; López-González FJ; Lorenzo-González JR; Marín-Sánchez M; Muñoz-García D; Ozaita-Arteche G; Prieto JM
Rev Neurol; 2003 Dec 1-15; 37(11):1001-4. PubMed ID: 14669137
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of Th17-related cytokines and receptors in multiple sclerosis patients under interferon β-1 therapy.
Esendagli G; Kurne AT; Sayat G; Kilic AK; Guc D; Karabudak R
J Neuroimmunol; 2013 Feb; 255(1-2):81-4. PubMed ID: 23177721
[TBL] [Abstract][Full Text] [Related]
19. Interferon-beta regulates cytokines and BDNF: greater effect in relapsing than in progressive multiple sclerosis.
Hamamcioglu K; Reder AT
Mult Scler; 2007 May; 13(4):459-70. PubMed ID: 17463069
[TBL] [Abstract][Full Text] [Related]
20. Beneficial effect of interferon-beta 1b treatment in patients with relapsing-remitting multiple sclerosis is associated with an increase in serum levels of soluble HLA-I molecules during the first 3 months of therapy.
Fainardi E; Rizzo R; Melchiorri L; Castellazzi M; Govoni V; Caniatti L; Paolino E; Tola MR; Granieri E; Baricordi OR
J Neuroimmunol; 2004 Mar; 148(1-2):206-11. PubMed ID: 14975603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]